Panaxynol, a bioactive component of American ginseng, targets macrophages and suppresses colitis in mice
Panaxynol, a bioactive component of American ginseng, targets macrophages and suppresses colitis in mice |
|
https://doi.org/10.18632/oncotarget.27592
Anusha Chaparala,
Deepak Poudyal,
Hossam Tashkandi,
Erin E. Witalison,
Alexander A. Chumanevich,
Jenna L. Hofseth,
Ivy Nguyen,
Olivia Hardy,
Douglas L. Pittman,
Michael D. Wyatt,
Anthony Windust,
Elizabeth A. Murphy,
Mitzi Nagarkatti,
Prakash Nagarkatti,
and Lorne J. Hofseth
|
| 2026-2036 |
HSP90 overexpression potentiates the B-cell receptor and fibroblast growth factor receptor survival signals in chronic lymphocytic leukemia cells
HSP90 overexpression potentiates the B-cell receptor and fibroblast growth factor receptor survival signals in chronic lymphocytic leukemia cells |
|
https://doi.org/10.18632/oncotarget.27409
Hasan Mahmud,
Mariana Mendez,
Bedabrata Mukhopadhyay,
Jennifer Holter-Chakrabarty,
and Asish K. Ghosh
|
| 2037-2046 |
Carcinogenetic initiation contributed by EpCAM+ cancer cells in orthotopic HCC models of immunocompetent and athymic mice
Carcinogenetic initiation contributed by EpCAM+ cancer cells in orthotopic HCC models of immunocompetent and athymic mice |
|
https://doi.org/10.18632/oncotarget.27454
Harshul Pandit,
Yan Li,
Qianqian Zheng,
Wei Guo,
Youxi Yu,
Suping Li,
and Robert C.G. Martin
|
| 2047-2060 |
Hereditary pancreatitis model by blastocyst complementation in mouse
Hereditary pancreatitis model by blastocyst complementation in mouse |
|
https://doi.org/10.18632/oncotarget.27595
Ayumu Asai,
Masamitsu Konno,
Koichi Kawamoto,
Ayako Isotani,
Masaki Mori,
Hidetoshi Eguchi,
Yuichiro Doki,
Takahiro Arai,
and Hideshi Ishii
|
| 2061-2073 |
Efficacy of osimertinib against EGFRvIII+ glioblastoma
Efficacy of osimertinib against EGFRvIII+ glioblastoma |
|
https://doi.org/10.18632/oncotarget.27599
Gustavo Chagoya,
Shawn G. Kwatra,
Cory W. Nanni,
Callie M. Roberts,
Samantha M. Phillips,
Sarah Nullmeyergh,
Samuel P. Gilmore,
Ivan Spasojevic,
David L. Corcoran,
Christopher C. Young,
Karla V. Ballman,
Rohan Ramakrishna,
Darren A. Cross,
James M. Markert,
Michael Lim,
Mark R. Gilbert,
Glenn J. Lesser,
and Madan M. Kwatra
|
| 2074-2082 |
Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting
Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting |
|
https://doi.org/10.18632/oncotarget.27603
Salvatore Del Prete,
Liliana Montella,
Grazia Arpino,
Giuseppe Buono,
Carlo Buonerba,
Pasquale Dolce,
Olga Fiorentino,
Maria Aliberti,
Antonio Febbraro,
Clementina Savastano,
Giuseppe Colantuoni,
Ferdinando Riccardi,
Angela Ruggiero,
Sabino De Placido,
and Michele Orditura
|
| 2083-2091 |
Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer
Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer |
|
https://doi.org/10.18632/oncotarget.27604
Anders Handrup Kverneland,
Magnus Pedersen,
Marie Christine Wulff Westergaard,
Morten Nielsen,
Troels Holz Borch,
Lars Rønn Olsen,
Gitte Aasbjerg,
Saskia J. Santegoets,
Sjoerd H. van der Burg,
Katy Milne,
Brad H. Nelson,
Özcan Met,
Marco Donia,
and Inge Marie Svane
|
| 2092-2105 |
Anticancer effect of physical activity is mediated by modulation of extracellular microRNA in blood
Anticancer effect of physical activity is mediated by modulation of extracellular microRNA in blood |
|
https://doi.org/10.18632/oncotarget.27609
Alessandra Pulliero,
Ming You,
Pradeep Chaluvally-Raghavan,
Barbara Marengo,
Cinzia Domenicotti,
Barbara Banelli,
Paolo Degan,
Luigi Molfetta,
Fabio Gianiorio,
and Alberto Izzotti
|
| 2106-2119 |
Review: Organic nanoparticle based active targeting for photodynamic therapy treatment of breast cancer cells
Review: Organic nanoparticle based active targeting for photodynamic therapy treatment of breast cancer cells |
|
https://doi.org/10.18632/oncotarget.27596
Hanieh Montaseri,
Cherie Ann Kruger,
and Heidi Abrahamse
|
| 2120-2136 |
Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation
Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation |
|
https://doi.org/10.18632/oncotarget.27598
Javier Molina-Cerrillo,
Teresa Alonso-Gordoa,
Alfredo Carrato,
and Enrique Grande
|
| 2137-2140 |
